Reminder: Invitation to Roche’s Investor Event at ASCO 2026 Donnerstag, 21. Mai 2026 - 16:50
| Investor Update |  |
The Roche Investor Relations team would like to invite you to an analyst and investor event on Tuesday, 2 June 2026, to highlight Roche's late stage oncology pipeline with a special focus on giredestrant, at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (May 29 - June 2, 2026).
Agenda Introduction Bruno Eschli, Head of Investor Relations
Roche oncology strategy and portfolio highlights Wendy Cheung, Therapeutic Area Head Oncology & Hematology, Global Product Strategy
Breast cancer franchise update Aakanksha Khandelwal, Disease Area Head Breast, Global Product Strategy
Giredestrant Ph III study results in breast cancer: evERA, persevERA, lidERA Aditya Bardia, MD, MPH, FASCO, Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Q&A
Meeting information Tuesday, 2 June 2026 1:00 – 2:00pm Registration & light lunch 2:00 – 3:30pm Presentations & Q&A
Venue Marriott Downtown Chicago 540 North Michigan Avenue 60611 Chicago
To register for the event, please follow this > link(passcode: ASCO2026) The slideswill be available for download at 1:00pm CDT on the day of the event.
Alternatively you may participate virtually in the webinar (access to speakers, pre-registration required). Please pre-register for the webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail toinvestor.relations@roche.com .
A replay of the event will be available via > ir.roche.com
Best regards,
| |
Bruno Eschli
| Rafal Pawlowski |
Roche Investor Relations |
|
Dr. Bruno Eschli | Dr. Sabine Borngräber |
Dr. Birgit Masjost |
|
|
|
Investor Relations North America |
|
Loren Kalm |
|
All rights reserved ©2026 F. Hoffmann-La Roche Ltd.
Group Communications, Grenzacherstrasse 124, CH-4070 Basel, Switzerland